Literature DB >> 23446746

Damage to pig bile duct caused by intraluminal brachytherapy using a (125)I ribbon.

Yi Chen1, Xiao-Lin Wang, Zhi-Ping Yan, Jian-Hua Wang, Jie-Min Cheng, Gao-Quan Gong, Guo-Ping Li.   

Abstract

BACKGROUND: Stent occlusion by tumor ingrowth or overgrowth is the main cause of jaundice recurrence after metal stent insertion in patients with malignant obstructive jaundice (MOJ). The application of intraluminal brachytherapy (ILBT) in patients with MOJ results in local control of malignant tumors, which prolong stent patency.
PURPOSE: To evaluate the safety of ILBT in pig bile ducts using ribbons of iodine-125 ((125)I) seeds.
MATERIAL AND METHODS: Sixteen healthy pigs were randomly assigned to four groups of four pigs each. A (125)I seed ribbon was implanted into the common bile duct of each animal through an incision in the duct wall, and was fixed by suturing. The four groups of animals were sacrificed at 15, 30, 60, and 120 days after ribbon implantation, respectively. Serum bilirubin concentrations, alanine aminotransferase concentrations, and white blood cell counts before and after implantation were compared within each group. Pathological changes to the bile duct wall were observed using a light microscope. Morphological changes in biliary epithelial cells and organelles were observed with electron microscopy.
RESULTS: (125)I ribbons were successfully implanted in all animals without surgery-related death. We found no significant difference in pre- and post-implant serum bilirubin, alanine aminotransferase, or white blood cell counts. Light and electron microscopy showed that the most severe bile duct damage occurred in the 15-day group, which exhibited necrosis and detachment of numerous epithelial cells, and infiltration of inflammatory cells. Repair and proliferation of the bile duct epithelium began 30 days after implantation and was nearly complete at 60 days.
CONCLUSION: This study demonstrated the safety of ILBT using a (125)I ribbon in the pig bile duct. (125)I seed ribbons may be used in the treatment of MOJ in humans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23446746     DOI: 10.1258/ar.2012.120214

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  7 in total

1.  Placement of ¹²⁵I seed strands and stents for a type IV Klatskin tumor.

Authors:  Wen Zhang; Zheng-Qiang Yang; Hai-Bin Shi; Shen Liu; Wei-Zhong Zhou; Lin-Bo Zhao
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

2.  Study of self-expandable metallic stent placement intraluminal 125I seed strands brachytherapy of malignant biliary obstruction.

Authors:  Dechao Jiao; Gang Wu; Jianzhuang Ren; Xinwei Han
Journal:  Surg Endosc       Date:  2017-06-22       Impact factor: 4.584

3.  In vitro Dosimetric Study of Biliary Stent Loaded with Radioactive 125I Seeds.

Authors:  Li-Hong Yao; Jun-Jie Wang; Charles Shang; Ping Jiang; Lei Lin; Hai-Tao Sun; Lu Liu; Hao Liu; Di He; Rui-Jie Yang
Journal:  Chin Med J (Engl)       Date:  2017-05-05       Impact factor: 2.628

4.  Biliary stent combined with iodine-125 seed strand implantation in malignant obstructive jaundice.

Authors:  Hui-Wen Wang; Xiao-Jing Li; Shi-Jie Li; Jun-Rong Lu; Dong-Feng He
Journal:  World J Clin Cases       Date:  2021-02-06       Impact factor: 1.337

5.  Self-expandable metallic stent with 125I seed strand in malignant biliary obstruction: a self-made delivery system and novel implantation method.

Authors:  Rui An; Hu Zhang; Jing Yu; Yunbao Cao; Jialiang Ren; Wangang Guo; Zhonghua Luo
Journal:  Ann Transl Med       Date:  2021-12

6.  Feasibility and efficacy of endoscopic ultrasound-guided iodine-125 seed implantation in inoperable ampullary carcinoma: initial clinical experience.

Authors:  Tingting Cui; Lianqiang Han; Nianjun Xiao; Fang Liu; Wen Li
Journal:  J Contemp Brachytherapy       Date:  2022-05-10

7.  Biliary self-expandable metallic stent combined with Iodine-125 seeds strand in the treatment of hilar malignant biliary obstruction.

Authors:  Chuanguo Zhou; Hui Li; Qiang Huang; Jianfeng Wang; Kun Gao
Journal:  J Int Med Res       Date:  2019-12-29       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.